dc.contributor.author | Göktaş Aydın, Sabin | |
dc.contributor.author | Bilici, Ahmet | |
dc.contributor.author | Çalış, Elif | |
dc.contributor.author | Kutlu, Yasin | |
dc.contributor.author | Hamdard, Jamshid | |
dc.contributor.author | Muğlu, Harun | |
dc.contributor.author | Ölmez, Ömer Fatih | |
dc.contributor.author | Karcı, Ebru | |
dc.contributor.author | Açıkgöz, Özgür | |
dc.date.accessioned | 2023-09-29T08:36:21Z | |
dc.date.available | 2023-09-29T08:36:21Z | |
dc.date.issued | 2023 | en_US |
dc.identifier.citation | Göktaş Aydın, S., Bilici, A., Çalış, E., Kutlu, Y., Hamdard, J., Muğlu, H. ... Açıkgöz, Ö. (2023). Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer. International Immunopharmacology, 124. https://doi.org/10.1016/j.intimp.2023.110947 | en_US |
dc.identifier.issn | 1567-5769 | |
dc.identifier.issn | 1878-1705 | |
dc.identifier.uri | https://doi.org/10.1016/j.intimp.2023.110947 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/11503 | |
dc.description.abstract | Background: Non-small cell lung cancer (NSCLC) often exhibits elevated Secreted Protein Acidic and Cysteine-Rich (SPARC) expression. In this study, we investigated the impact of SPARC expression on clinicopathologic features, pembrolizumab response, and prognosis in metastatic NSCLC patients. Methods: Thirty-six patients diagnosed with metastatic NSCLC without actionable driver mutation and who received pembrolizumab with or without chemotherapy were included in this study. PD-L1 and SPARC expression were evaluated, with PD-L1 expression categorized based on tumor proportion score and SPARC staining intensity graded as 1+, 2+, and 3 +. Patients’ characteristics were compared across groups, and possible predictive markers were determined by binary logistic regression analysis. Results: No significant associations were found between SPARC expression and smoking status, histopathological tumor type, T and N status, and liver and bone metastasis. Higher SPARC expression was significantly linked to lower brain metastasis rates but higher CNS progression rates (p = 0.022 and p = 0.011, respectively. The objective response rate (ORR) showed a trend of being higher in the SPARC 1 + group (85.7% vs. 43.8% and 50.0% in 2 + and 3 + groups, respectively, p = 0.052. Univariate analysis did not find SPARC expression to be a significant prognostic factor for progression-free survival (PFS) (p = 0.7) and overall survival (OS) (p = 0.07).SPARC 1 + expression negatively affected the pembrolizumab response(p = 0.04,OR:0.11, 95%CI 0.01–0.92). Conclusions: Our study sheds light on a novel aspect of SPARC expression as a potential predictor of pembrolizumab response and a marker for CNS progression in metastatic NSCLC patients treated in the first-line setting. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier B.V. | en_US |
dc.rights | info:eu-repo/semantics/embargoedAccess | en_US |
dc.subject | Non-Small Cell Lung Cancer | en_US |
dc.subject | Pembrolizumab | en_US |
dc.subject | Response | en_US |
dc.subject | SPARC Expression | en_US |
dc.title | Impact of SPARC expression on treatment response of pembrolizumab and brain metastasis in patients with metastatic non-small cell lung cancer | en_US |
dc.type | article | en_US |
dc.relation.ispartof | International Immunopharmacology | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Tıbbi Patoloji Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-0077-6971 | en_US |
dc.authorid | 0000-0002-0443-6966 | en_US |
dc.authorid | 0000-0002-0600-5801 | en_US |
dc.authorid | 0000-0002-5823-1704 | en_US |
dc.authorid | 0000-0001-7934-7039 | en_US |
dc.authorid | 0000-0001-8802-6376 | en_US |
dc.authorid | 0000-0003-2715-4002 | en_US |
dc.identifier.volume | 124 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1016/j.intimp.2023.110947 | en_US |
dc.institutionauthor | Göktaş Aydın, Sabin | |
dc.institutionauthor | Bilici, Ahmet | |
dc.institutionauthor | Çalış, Elif | |
dc.institutionauthor | Kutlu, Yasin | |
dc.institutionauthor | Hamdard, Jamshid | |
dc.institutionauthor | Muğlu, Harun | |
dc.institutionauthor | Ölmez, Ömer Fatih | |
dc.institutionauthor | Karcı, Ebru | |
dc.institutionauthor | Açıkgöz, Özgür | |
dc.identifier.wosquality | Q1 | en_US |
dc.identifier.wos | 001082097100001 | en_US |
dc.identifier.scopus | 2-s2.0-85171857922 | en_US |
dc.identifier.pmid | 37742369 | en_US |
dc.identifier.scopusquality | Q1 | en_US |